Exact Sciences Corporation

About Exact Sciences Corporation

Exact Sciences Corporation develops and commercializes molecular diagnostic tests for early detection and prevention of cancer. The Madison, Wisconsin–based company’s flagship Cologuard and Cologuard Plus assays screen for colorectal cancer using stool-based DNA and biomarker analysis. It also offers the Oncotype DX portfolio to guide breast, prostate and colon cancer therapy decisions, and the multi-cancer blood test FirstSight. Through acquisitions and partnerships, Exact Sciences is building a pipeline of liquid-biopsy tests aimed at lung, pancreatic, liver and other cancers, while providing laboratory services and precision oncology tools to hospitals, physicians and patients worldwide.